The October 13, 2026, Form 4 filing reports a trade dated October 8, 2026. This SEC report of insider stock activity names Anderman Todd, chief legal officer of Ocular Therapeutix (OCUL).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-08 |
| Date of Latest Transaction | 2026-10-08 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 11,984 |
| Price | $7.29 |
| Total Transaction Value | $87,363.36 |
| Insider | |
| Ticker Symbol | OCUL |
| Company | OCULAR THERAPEUTIX, INC |
| Insider Name | Anderman Todd |
| Insider Title | Chief Legal Officer |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 140,484 |
| Position Size Change | 7.86% |
| Filing | |
| Filing Date | 2026-10-13 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was one sale of Ocular Therapeutix shares, reported with transaction code S.
What was the average price of the transaction?
The average sale price was $7.29 per share.
How did this transaction affect the insider's holdings?
Anderman Todd sold 11,984 shares and reported 140,484 shares owned afterward. The sale represented 7.86% of the shares he owned before the sale.
What's the total transaction value?
The total value of the one reported sale was $87,363.36.
Are there any special circumstances around this transaction?
The transaction information points to a Rule 10b5-1 plan reference and a tax coverage link. A Rule 10b5-1 plan sets trading instructions in advance. The reference may apply to the filing as a whole. No footnote text was provided to show whether the plan covered this specific sale. The plan's terms and adoption date are unknown.
The tax coverage information points to a payment tied to stock compensation. Stock compensation means pay through shares or rights to shares. Here, code S records a sale of shares. Without the footnotes, the exact tax or payment purpose is unclear. It is unknown whether taxes were the only purpose.
For research purposes only; not investment advice.